Articles tagged with Fibrosis
Researchers found that transplanting B10 human bone marrow-derived mesenchymal stem cells into the bladder wall of mice with spinal cord injury improved bladder function by promoting the growth of smooth muscle cells. This study provides potential evidence for MSC-based cell transplantation as a novel therapeutic strategy for bladder d...
A study has identified chitinase 3-like-1 (CHI3L1) as the master regulator of idiopathic pulmonary fibrosis (IPF), a devastating lung disease. CHI3L1 plays a dual role in promoting tissue repair and reducing cell death, but its chronic elevation contributes to excessive scarring and tissue dysfunction.
Two drugs, pirfenidone and nintedanib, have been found to slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease. Researchers conducted multicenter clinical trials to test their efficacy.
Researchers at the University of Illinois Chicago have discovered a protein molecule that slows the progression of pulmonary fibrosis, a deadly lung disease. The protein, LYCAT, is found to be protective and may boost survival rates in patients with idiopathic pulmonary fibrosis.
Bariatric surgery resolves liver inflammation and reverses early-stage liver fibrosis by reducing fat deposits in the liver. The procedure showed significant improvement in nonalcoholic fatty liver disease (NAFLD) in severely obese patients.
A new study reveals that even light drinking increases the risk of liver fibrosis in people co-infected with HIV and hepatitis C virus (HCV) infection. Researchers found a stark difference between co-infected and uninfected groups, highlighting the importance of counseling patients to reduce alcohol consumption.
A Northwestern University discovery identifies a specific protein, fibronectin (FnEDA), as a key player in promoting fibrosis in people with scleroderma. The study found that blocking this protein's activity can prevent skin fibrosis in mice, offering new avenues for treatment.
Researchers at Michigan State University have identified the core signaling pathway that activates scleroderma and found chemical compounds that can turn it off. This discovery offers a new approach to treating the disease, which currently lacks effective treatments.
Scientists at the University of Sheffield have developed a novel antibody-based therapy to target fibrosis progression. The treatment blocks key enzyme action and may also work for lung, liver, and heart fibrosis.
A Cedars-Sinai research team led by Paul W. Noble is developing a novel approach to treat idiopathic pulmonary fibrosis, a disease that destroys the lungs and damages vital organs. The two-year study aims to build upon preliminary research and uncover the precise way normal lung stem cell repair occurs.
Scientists at Saint Louis University have discovered a potential novel therapeutic approach to treat fibrotic diseases by targeting the Transforming Growth Factor (TGF) beta protein. Removing a gene that makes alpha v integrins blocks TGF beta activation, and treatment with a small molecule compound replicates this effect.
Research published in Hepatology suggests that estrogen has a protective effect against the development of severe liver fibrosis in patients with nonalcoholic steatohepatitis (NASH). The study found that men and post-menopausal women have similar risks of developing severe fibrosis compared to pre-menopausal women.
Researchers at the University of Tsukuba have identified a synthetic ligand that reduces renal fibrosis in mice by inhibiting the TGF-β/SMAD signaling pathway. This finding has implications for the treatment of patients with fibrotic diseases.
Researchers found ionizing radiation exposure promotes formation of fusion oncogenes in papillary thyroid cancers. In another study, the origin of lethal prostate cancer was traced back to a small, low-grade focus in the primary tumor. Additionally, reduced reactive oxygen species production in diabetic kidneys may contribute to diseas...
Researchers at Johns Hopkins Medicine have identified a defect in cell communication as the likely cause of systemic sclerosis, a disease affecting approximately 100,000 people in the US. They also developed treatment strategies using compounds that target the immune response and fibrosis.
A new imaging technique, MRE, can accurately detect fibrosis in children with chronic liver disease, including non-alcoholic fatty liver disease. The study showed high accuracy in detecting advanced fibrosis in obese patients, potentially reducing the need for costly and invasive liver biopsies.
Myocardial interstitial fibrosis is a major therapeutic target for the prevention and treatment of heart failure. The FIBRO-TARGETS project will accurately identify key mechanisms involved in fibrosis and define therapeutic approaches to target these mechanisms.
A new study shows that magnetic resonance imaging (MRI) can stage the degree of damaged heart tissue and help predict whether treatment will be successful. Patients with early-stage atrial fibrosis have a higher chance of being cured, while those with late-stage fibrosis have a lower success rate.
A recent study published in Immunity has identified interleukin-33 as a central factor in the formation of liver fibrosis. The research suggests that targeting this molecule could provide a promising new approach to protecting against liver fibrosis and chronic liver disease.
A study published in Spine Journal found that 65% of herniated lumbar discs resulted from avulsion of the vertebral end plate junction, rather than true rupture. The findings challenge conventional wisdom on how herniated discs occur and may lead to a reevaluation of treatment strategies.
Scientists have identified four pathways involved in the formation of myofibroblasts that drive destructive runaway scarring in organs. These pathways provide leads for drug targets to control fibrosis.
Researchers found a genetic risk factor for pulmonary fibrosis in people with the MUC5B gene variant, associated with increased lung inflammation and scarring. The study suggests that pulmonary fibrosis may be part of a larger syndrome, potentially leading to early detection and treatment.
A study published in JAMA found that a specific genetic variation is associated with improved survival in some cases of pulmonary fibrosis. The researchers identified the MUC5B promoter polymorphism as a key factor, which may lead to the development of new treatments for this deadly lung disease.
A common genetic variant of the MUC5B gene is linked to an increased risk of interstitial lung disease and symptoms such as shortness of breath and cough. The study suggests that this variant may be a key indicator for predicting individuals at risk for pulmonary fibrosis, potentially paving the way for prevention efforts.
A study published in JAMA Network found that genetic variation in the MUC5B gene is associated with improved survival rates among patients with pulmonary fibrosis. The research suggests that this genetic variant can be used to predict mortality in these patients, providing new insights into the underlying mechanisms of the disease.
Scientists at the Salk Institute have discovered that a synthetic form of vitamin D can deactivate the switch governing fibrotic response in mouse liver cells, suggesting a potential new therapy for fibrotic diseases. This finding could lead to the development of a safer and more effective treatment for liver fibrosis.
A genome-wide association study of over 6,000 people has identified seven new genetic regions linked to pulmonary fibrosis. The research provides clues to the disease's mechanisms and suggests a possible connection between genetic variants and environmental factors.
A genome-wide association study identified a novel genetic locus linked to both the onset and mortality of idiopathic pulmonary fibrosis. The study found that a variant in the TOLLIP gene was associated with an increased risk of death, suggesting an abnormal immune response may be central to the disease.
Pulmonary fibrosis is a condition where lung tissue becomes thickened and scarred, with no approved drugs for its most common form. A new study found that genetic variation accounts for approximately one-third of the risk, identifying seven novel genetic risk loci involved in host defense, cell-cell adhesion, and DNA repair.
Researchers have identified two key compounds produced by mast cells that promote fibrogenesis, leading to pulmonary fibrosis. Introducing mast cells into mice lungs can reverse disease protection and cause pulmonary fibrosis.
Patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis do not have higher mortality risk, according to new research. However, those likely to progress to advanced fibrosis had a 69% increase in mortality compared to those without fibrosis.
Researchers found that blocking an enzyme promoting inflammation can prevent cardiac tissue damage and fibrosis after a heart attack. The study's results show improved cardiac function and reduced inflammatory factors in mice treated with the compound.
Midwall fibrosis detected via MRI is associated with higher mortality rates in patients with nonischemic dilated cardiomyopathy. Patients with midwall fibrosis are at an increased risk of sudden cardiac death and cardiovascular mortality.
Scientists successfully use parthenogenic stem cells to develop functional heart muscle and treat pulmonary fibrosis. Researchers find that inhibiting a protein called ROCK attenuates myofibroblast survival and prevents lung scarring.
Pulmonary fibrosis is a scarring of the lungs that causes shortness of breath and fatigue. Researchers identified a mechanosensitive cellular signaling pathway in myofibroblasts, which promotes survival and prevents normal cell disappearance after wound healing.
Research at Oregon State University found that DHA supplementation reduced liver fibrosis by over 65% in laboratory animals. This study suggests that DHA may be a more effective dietary supplement than EPA for preventing nonalcoholic steatohepatitis (NASH) and other liver diseases.
Research reveals that a protein called IL-13 plays a crucial role in the development of fibrosis in Crohn's disease. The study found that increased levels of IL-13 lead to excessive collagen synthesis and tissue hardening, causing bowel narrowing and loss of mobility.
Mount Sinai researchers have developed a playbook for treating fibrotic diseases, which are responsible for 45% of all deaths in the industrialized world. They've identified promising experimental drugs and biomarkers that will facilitate testing of new treatments.
Achieving sustained virological response (SVR) to interferon-based treatment is associated with lower all-cause mortality and reduced risk of liver-related complications in patients with chronic HCV infection. SVR was linked to a prolonged overall survival, with a 4-fold lower risk of all-cause mortality compared to those without SVR.
Researchers at Northwestern University have implicated toll-like receptor 4 (TLR4) in the development of tissue fibrosis, a hallmark of scleroderma. The study found that mutations in the TLR4 gene made mice resistant to experimental scleroderma and that patients with scleroderma had abnormal TLR4 levels in affected tissues.
Researchers found that JHQG significantly prolonged survival in patients with non-small cell lung cancer (NSCLC), improved quality of life and activity capacity in IPF patients, and reduced fever in influenza patients compared to standard care and placebo.
Scientists at Cincinnati Children's Hospital Medical Center identify a molecular pathway critical to body repair processes after injury, leading to potential new anti-fibrotic or anti-inflammatory agents. The discovery could provide a targeted intervention point in fibrotic diseases, including heart failure and muscular dystrophy.
Researchers found thalidomide significantly reduced the cough and improved quality of life for patients with idiopathic pulmonary fibrosis. The constant cough caused by IPF can have wide-ranging effects on patients' lives, affecting daily activities and social gatherings.
Galectin-3 protein has been linked to an increased risk of heart failure and death in older adults, according to a new study. The study found that individuals with high levels of galectin-3 were more likely to experience heart failure, highlighting the potential for measuring blood levels as an early warning sign.
A new 'traffic light' test can diagnose liver fibrosis and cirrhosis in high-risk populations more easily than current methods. The test provides a color-coded system, with red indicating scarring, green indicating no cirrhosis, and amber indicating a 50:50 chance of scarring.
A study published in Hepatology reports a promising new therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to organ failure. The NADPH oxidase inhibitor GKT137831 was found to suppress fibrotic gene expression and prevent further fibrosis in mouse models.
Researchers at the University of Michigan have discovered a new single-gene cause of chronic kidney disease, which implicates DNA damage response signaling. The study found that mutations in Fanconi anemia-associated nuclease 1 (FAN1) lead to increased DNA damage and apoptosis in patients with CKD.
Researchers at the University of Pittsburgh School of Medicine have identified an agent called E4 that can protect the skin and lungs from fibrosis, a process that can lead to organ failure and death. The agent may work by stalling the cross-linking of collagen needed to form thick scars.
Research shows that lung transplant patients receiving organs from smokers tend to survive longer than those waiting on the list, with significant benefits for patients with septic lung disease and fibrosis. The UK's current selection policy of including both smoking and non-smoking donors improves survival rates and should be continued.
A recent study has found that sarcoidosis accounts for 25% of all deaths among black women with the disease, emphasizing the need for early detection and treatment. The study also highlights the severity of pulmonary disease in black women with sarcoidosis, with respiratory failure being a leading cause of death.
African Americans with systemic sclerosis have higher frequencies of certain autoantibodies, associated with increased frequency and severity of pulmonary fibrosis and decreased survival. The study highlights the need for more aggressive treatment for African-American patients with severe lung disease.
African-Americans with systemic scleroderma have more antibodies that link to severe complications and increased mortality compared to Caucasians. The study suggests using disease markers to screen and treat patients proactively.
Scientists at the University of California, San Diego School of Medicine found that activated myofibroblasts can revert to an inactive phenotype during liver healing, suggesting a potential treatment approach for reversing fibrosis. This discovery has implications for treating not only liver but also lung and kidney fibrosis.
Michael Young, a lung transplant recipient, credits his new lungs for giving him the joy of breathing again. His remarkable survival story highlights UT Southwestern's exceptional Lung Transplant Program, with an 86% one-year and 75% three-year survival rate.
Two studies found that severe fibrosis increases the risk of developing atherosclerosis at an earlier period. Fatty liver disease also increases risk, with GGT levels serving as a potential biomarker for early atherosclerosis.
Fibronectin play a crucial role in wound healing and embryonic development, but its role in disease progression is not well understood. Researchers have identified molecular probes that can selectively attach to fibronectin fibers under different strain states, enabling the detection of strain events in both culture and living tissues.
A recent study published in Nature Communications has identified a key component regulating pulmonary fibrosis, a fatal disease with currently no cure. The researchers found that the CLYD gene serves as a crucial negative regulator, halting disease progression and potentially opening new avenues for treatment.
Researchers at Mount Sinai School of Medicine have identified HIPK2 as a crucial regulator protein in kidney fibrosis, leading to improved conditions when eliminated or inhibited. The study provides a new therapeutic target for the treatment of kidney failure, affecting millions of Americans.
Researchers at Beth Israel Deaconess Medical Center have identified a key molecular player that can reverse kidney damage in mouse models of diabetes and other kidney injuries. The targeted experimental drug has shown to suppress inflammation, cell death, and fibrosis formation, allowing normal tissue to regenerate.
A recent study published in Liver Transplantation confirms that ultrasound-based transient elastography is an effective diagnostic tool for detecting cirrhosis caused by recurrent hepatitis C following liver transplantation. The non-invasive technology offers quick and painless assessment, with high sensitivity and specificity estimates.